Androgen induction of urokinase gene expression in LNCaP cells is dependent on their interaction with the extracellular matrix

Cancer Letters

Volumn 130, Issue 1-2, 1998, Pages 121-126

  Pentyala, Srinivas N ^a   Whyard, Terry C ^a   Waltzer, Wayne C ^a   Meek, Alan G ^a   Hod, Yaacov ^a  

^a STONY BROOK UNIVERSITY   (United States)

Author keywords

Dihydrotestosterone; Fibronectin; LNCaP cells; Urokinase plasminogen activator; Urokinase plasminogen activator receptor

Indexed keywords

ANDROGEN; ANDROSTANOLONE; FIBRONECTIN; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CELL INVASION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

DIHYDROTESTOSTERONE; EXTRACELLULAR MATRIX; EXTRACELLULAR MATRIX PROTEINS; FIBRONECTINS; GENE EXPRESSION; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; RECEPTORS, CELL SURFACE; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 0032516681     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(98)00120-7     Document Type: Article

References (33)

1. Mignatti P., Rifkin D.B. Biology and biochemistry of proteinases in tumor invasion. Physiol. Rev. 73:1993;161-195.
2. Blasi F., Vassalli J.K., Dano K. Urokinase-type plasminogen activator: proenzyme, receptor and inhibitors. J. Cell Biol. 104:1987;801-804.
3. Plow E.F., Herren T., Redlitz A., Miles L.A., Hoover-Plow J.L. The cell biology of the plasminogen system. FASEB J. 9:1995;939-945.
4. Vassalli J.D., Baccino D., Belin D. A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J. Cell Biol. 100:1985;86-92.
5. Pepper M.S., Sappino A.P., Stocklin R., Montesano R., Orci L., Vassalli J.D. Upregulation of urokinase receptor expression on migrating endothelial cells. J. Cell Biol. 122:1993;673-684.
6. Estreicher A., Muhlhauser J., Carpentier J.L., Orci L., Vassalli J.D. The receptor of urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes. J. Cell Biol. 111:1990;783-792.
7. Jones P.L., Schmidhauser C., Bissell M.J. Regulation of gene expression and cell function by extracellular matrix. Crit. Rev. Eukaryotic Gene Expr. 3:1993;137-154.
8. Pollanen J., Hedman K., Nielsen L.A., Dano K., Vaheri A. Ultrastructural localization of plasma membrane associated urokinase-type plasminogen activator at focal contacts. J. Cell Biol. 106:1988;87-95.
9. Wei Y., Waltz D.A., Rao N., Drummond R.J., Rosenberg S., Chapman H.A. Identification of the urokinase receptor as an adhesion receptor for vitronectin. J. Biol. Chem. 269:1994;32380-32388.
10. Kosir M.A., Quinn C.C. Sorting of heperan sulfate proteoglycan into matrix components of prostate adenocarcinoma cells. J. Surg. Res. 58:1995;46-52.
11. Goodly L.J., Singh R.K., Wang M.H., Siegal G.P. In vivo modulation of human tumor cell growth by normal human extracellular matrix. Tumor Biol. 15:1994;326-336.
12. Soff G.A., Sanderowitz J., Gately S., Verrusio E., Weiss I., Brem S., Kwaan H.C. Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis and metastasis to lung and liver in an athymic mouse model. J. Clin. Invest. 96:1995;2593-2600.
13. Rabbani S.A., Harakidas P., Davidson D.J., Henkin J., Mazar A.P. Prevention of prostate cancer metastasis in vivo by a novel synthetic inhibitor of urokinase-type plasminogen activator. Int. J. Cancer. 63:1995;840-845.
14. Hollas W., Hoosein N., Chung L.W., Mazar A., Henkin J., Kariko K., Barnathan E.S., Boyd D. Expression of urokinase and its receptor in invasive and non-invasive prostate cancer cell lines. Thromb. Haemostas. 68:1992;662-666.
15. Sipley J.D., Alexander D.S., Testa J.E., Quigley J.P. Introduction of an RRHR motif into chicken urokinase-type plasminogen activator (ch-uPA) confers sensitivity to plasminogen activator inhibitor (PAI)-1 and PAI-2 and allows ch-uPA-mediated extracellular matrix degradation to be controlled by PAI-1. Proc. Natl. Acad. Sci. USA. 94:1997;2933-2938.
16. Berns E.M.J.J., de Boer W., Mulder E. Androgen dependent growth regulation of and release of specific protein(s) by the androgen receptor containing human prostate tumor cell line LNCaP. Prostate. 9:1986;247-259.
17. Chapman H.A., Vavrin Z., Hibbs J.B. Macrophage fibrinolytic activity: identification of two pathways of plasmin formation by intact cells and of a plasminogen activator inhibitor. Cell. 28:1982;653-662.
18. Stack S., Gray R.D., Pizzo S.V. Modulation of plasminogen activation and type IV collagenase activity by a synthetic peptide derived from laminin A chain. Biochemistry. 30:1991;2073-2077.
19. Khan K.M.F., Falcone D.J. Role of laminin in matrix induction of macrophage urokinase-type plasminogen activator and 92-kDa metalloproteinase expression. J. Biol. Chem. 272:1997;8270-8275.
20. Ruoslahti E. Fibronectin and its receptors. Annu. Rev. Biochem. 57:1988;375-413.
21. Cunha G.R., Donjacour A.A., Cooke P.S., Mee S., Bigsby R.M., Higgins S.J., Sugimura Y. The endocrinology and developmental biology of the prostate. Endocrinol. Rev. 8:1987;338-362.
22. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science. 240:1988;889-895.
23. Taplin M.E., Bubley G.J., Shuster T.D., Frantz M.E., Spooner A.E., Ogata G.K., Keer H.N., Balk S.P. Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N. Engl. J. Med. 332:1995;1393-1398.
24. Cress A.E., Rabinovitz I., Zhu W., Nagle R.B. The α6β1 and α6β4 integrins in human prostate cancer progression. Cancer Met. Rev. 14:1995;219-228.
25. Frisch S.M., Francis H. Disruption of epithelial cell-matrix interactions induces apoptosis. J. Cell Biol. 124:1994;619-626.
26. Schwartz M.A., Schaller M.D., Ginsberg M.H. Integrins: emerging paradigms of signal transduction. Annu. Rev. Cell. Dev. Biol. 11:1995;549-599.
27. Clark E.A., Hynes R.O. Ras activation is necessary for integrin-mediated activation of extracellular signal-regulated kinase 2 and cytosolic phospholipase A2 but not for cytoskeletal organization. J. Biol. Chem. 271:1996;14814-14818.
28. Chen Q., Lin T.H., Der C.J., Juliano R.L. Integrin-mediated activation of MEK and mitogen-activated protein kinase is independent of Ras. J. Biol. Chem. 271:1996;18122-18127.
29. Schulze A., Zerfass-Thome K., Berges J., Middendorp S., Jansen-Durr P., Henglein B. Anchorage-dependent transcription of Cyclin A gene. Mol. Cell. Biol. 16:1996;4632-4638.
30. Lin T.A., Kong X., Haystead T.A., Pause A., Belsham G., Sonenberg N., Lawrence J.C. PHAS-I as a link between mitogen-activated protein kinase and translation initiation. Science. 266:1994;653-656.
31. Lee C., Sutkowski D.M., Sensibar J.A., Zelner D., Kim I., Amsel I., Shaw N., Prins G.S., Kozlowski J.M. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by DHT. Endocrinology. 136:1995;796-803.
32. Kasper S., Rennie P.S., Bruchovsky N., Sheppard P.C., Cheng H., Lin L., Shiu R.P., Snoek R., Matusik R.J. Cooperative binding of androgen receptors to two DNA sequences is required for androgen induction of the probasin gene. J. Biol. Chem. 269:1994;31763-31769.
33. Liu X.H., Wiley H.S., Meikle A.W. Androgens regulate proliferation of human prostate cancer cells in culture by increasing transforming growth factor-alpha (TGF-alpha) and epidermal growth factor (EGF)/TGF-alpha receptor. J. Clin. Endocrinol. Metab. 77:1993;1472-1478.